Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | CFTR | P13569 | 4/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | TYMP | P19971 | 2/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | TACR2 | P21452 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9073051 | 0.98 | TAAR1 (0.52) | MEN1KMT2ASMN1; SMN2KCNH2TAAR1 | |
| SCHEMBL11910714 | 0.91 | TAAR1 (0.54) | MEN1KMT2ASMN1; SMN2KCNH2TAAR1 | |
| SCHEMBL18567611 | 0.90 | MEN1 (0.47) | MEN1KMT2ASMN1; SMN2KCNH2TAAR1 | |
| SCHEMBL4428349 | 0.89 | TAAR1 (0.61) | MEN1KMT2ASMN1; SMN2TAAR1KDM4E | |
| SCHEMBL12656340 | 0.88 | MEN1 (0.45) | MEN1KMT2ASMN1; SMN2KCNH2TAAR1 | |
| SCHEMBL14158501 | 0.87 | BID (0.47) | MEN1KMT2ASMN1; SMN2CFTRKDM4E | |
| SCHEMBL15995365 | 0.87 | BID (0.47) | MEN1KMT2ASMN1; SMN2CFTRKDM4E | |
| SCHEMBL30695756 | 0.87 | BID (0.47) | MEN1KMT2ASMN1; SMN2CFTRKDM4E | |
| SCHEMBL27967827 | 0.87 | BID (0.47) | MEN1KMT2ASMN1; SMN2CFTRKDM4E | |
| SCHEMBL14158807 | 0.84 | CFTR (0.48) | MEN1KMT2ASMN1; SMN2CFTRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968211-B1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO PHARM SOLUTIONS CO LTD (KR) | 2021-05-12 | — | — | EP | disclosed |
| US-9951074-B2 | Dihydropteridinone derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-2527314-B1 | Process for preparation of phenyl carbamate derivatives | BIO-PHARM SOLUTIONS CO LTD (KR) | 2017-10-04 | — | — | EP | disclosed |
| EP-2797878-B1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING STROKE | BIO-PHARM SOLUTIONS CO LTD (KR) | 2017-08-16 | — | — | EP | disclosed |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| EP-2797880-B1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY | BIO-PHARM SOLUTIONS CO LTD (KR) | 2017-03-01 | — | — | EP | disclosed |
| EP-0915867-A1 | THIENYLCYCLOHEXANE DERIVATIVES FOR THIENYLCYCLOHEXYL SYNTHESIS | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998003498-A1 | THIENYLCYCLOHEXANE DERIVATIVES FOR THIENYLCYCLOHEXYL SYNTHESIS | SOCIETE D'EXPANSION SCIENTIFIQUE EXPANSIA (FR) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRD3 | MEN1 2473/4885KMT2A 1790/4885SMN1; SMN2 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.